BullsEye Insights

BullsEye: Daily London AIM RNS Round-Up

Thursday 14 May 2020


Here is our summary of the day's hottest RNS alerts from across London's Alternative Investments Market (AIM).


ImmuPharma Plc (IMM.L)

Efforts in fight vs Covid-19 with Lupuzor; Ureka

ImmuPharma PLC, the specialist drug discovery and development company provided a progress update on activities around Covid-19.

On 30 March 2020, ImmuPharma announced that it had expanded its pipeline to include three new 'Anti-Infective' programs, one of which was in 'Antivirals'. Investigation of the application of the Ureka peptide technologies within this Antivirals program suggests the potential to create effective anti-fusion peptides with the goal to prevent virus entry into the host cells, which may lead to novel peptide based antiviral therapies. Further exploratory work continues on this program.

As part of an overall evaluation of how we might apply our patented technologies to the fight against the Covid-19 epidemic, within our 'Autoimmunity' therapy  area, we have also been considering the unique way that Lupuzor ™ interacts with the immune system and any potential application to Covid-19.

In this respect we note the results* of a recent study conducted at Emory University Atlanta GA,  suggesting that Covid-19 (SARS-COV-2) patients and systemic lupus erythematosus (SLE) patients experiencing flares might share similar inflammatory symptoms, underpinned by similar mechanisms (role of cytokines). Lupuzor ™ is a modulator of the immune response and an anti-inflammatory agent, which has activity against SLE (lupus), an autoimmune disease, as well as against other inflammatory diseases. ImmuPharma, together with its US licencing partner, Avion Pharmaceuticals, will be progressing  Lupuzor ™ into a new optimised international Phase III trial this year in lupus patients.

Given the findings of the Atlanta research group, we postulate that Lupuzor ™ may help to reduce or perhaps prevent the occurrence of the cytokine storm seen in Covid-19 patients. Further exploratory work is ongoing to assess Lupuzor's ™ possible potential and clinical program in Covid-19 patients.


For the full RNS, see: https://www.investegate.co.uk/immupharma-plc--imm-/rns/efforts-in-fight-vs-covid-19-with-lupuzor--ureka/202005140700088372M/


React Group Plc (REAT.L)

Material contract award

REACT Group Plc, the leading specialist cleaning, hygiene and decontamination company announced it has been awarded a contract to provide specialist deep cleaning services on a regular basis to one of its Tier-1 Customers operating in the rail sector.  This is part of essential services and not COVID-19 related.


The initial contract, worth approximately £400k, will run for a period of 35-weeks through to the end of the calendar year and is incremental to the work REACT carries out for this customer on a regular basis.


Shaun Doak, Chief Executive Officer, commented;

"REACT are quickly becoming the 'go to' deep cleaning specialist for a number of Clients, especially those that operate facilities where cleanliness and hygiene are highly valued.  This contract provides further continuity and revenue visibility for the current year and into the next.  It comes as a direct result of our standout performance elsewhere for this Client and is a strong endorsement of our market-leading expertise."


For full RNS details, see: https://www.investegate.co.uk/react-group-plc--reat-/rns/material-contract-award/202005140700088371M/


Mountfield Group (MOGP.L)

Contract Win of £1.2m at CAF

The Directors of Mountfield Group Plc announce that CAF has won a contract with a value of £1.2m to install 30,000m2 of raised access flooring for a commercial office refurbishment project at Canary Wharf, London.

Installation works are due to commence in May and are expected to be substantially completed by the end of June 2020. The project is currently live on site and methods of working and safety procedures have been tailored to meet the requirements introduced to protect site workers against the impact of COVID-19.

Group CEO, Andy Collins said:

"We are delighted to have won this contract during this difficult period.  It comes at a time when activity levels in terms of contract tendering and business enquiries are high which we consider is a good indication that there is demand for the services of companies such as CAF as the country returns to work in the coming weeks."


For full RNS details, see: https://www.investegate.co.uk/mountfield-group--mogp-/rns/contract-win-of--1-2m-at-caf/202005140700098409M/

Download the BullsEye app for your phone or tablet

AppStore.png
playstore.png

*tap here*